Levodopa (Inbrija) vs Melevodopa/carbidopa (Sirio)

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Parkinson's Disease

Shared mechanism: dopamine precursor · full Parkinson's Disease pipeline

Levodopa (Inbrija)

Marketed by Merz Therapeutics and partners

Approved in Parkinson's Diseasesmall molecule
Partial signal

NCT02240030 · Phase 3 · completed

This randomized, double-blind, placebo-controlled phase 3 trial assigned 351 participants to CVT-301 60 mg, CVT-301 84 mg or placebo. Its clinical primary endpoint, the change in UPDRS motor score from predose to 30 minutes post-dose at week 12 for 84 mg versus placebo, was met: -9.83 versus -5.91, a difference of -3.92 points (95% CI -6.84 to -1.00; p=0.0088), as reported in the peer-reviewed publication.

Reported efficacy

Unified Parkinson's Disease Rating Scale (UPDRS) Part III (30 minutes post-dose at week 12): UPDRS motor score change, predose to 30 min post-dose at week 12: CVT-301 84 mg -9.83 vs placebo -5.91; difference -3.92 (95% CI -6.84 to -1.00), p=0.0088 (LeWitt et al., Lancet Neurol 2019) (met)

Result source: NCT02240030

Melevodopa/carbidopa (Sirio)

Marketed by Chiesi Farmaceutici

Phase 1/2 in Parkinson's Diseasesmall molecule
Partial signal

NCT00491998 · Phase 1/2 · completed

The study was randomized and double-blind, with a planned enrollment of 27 participants and a comparison with standard levodopa/carbidopa tablets. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.

Reported efficacy

to characterise the plasma concentrations of L-dopa after repeated doses of V1512 in fluctuating PD patients compared to standard L-dopa/carbidopa (Sinemet) over the course of the day (4 weeks): L-dopa accumulation from first to final dose across Cohorts 1/2/3: mean AUC0-t increase V1512 51%/50%/85% vs standard L-dopa/carbidopa 92%/93%/150%; mean Cmax increase V1512 30%/14%/52% vs standard 64%/23%/99%. (not_applicable)

Result source: NCT00491998

Results for Parkinson's Disease

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointLevodopa (Inbrija)Melevodopa/​carbidopa (Sirio)
OFF time, change—Not reported—Not reported
ON time without troublesome dyskinesia, change—Not reported—Not reported
UPDRS Part III, change-9.8 vs -5.9−3.9 vs placebowk 12 · n 114NCT02240030
4 other results
  • -8.5 vs -6.5 wk 12 · n 113 · Phase 3 · secondary NCT02240030
  • -9.0 vs -6.5 wk 12 · n 114 · Phase 3 · secondary NCT02240030
  • -5.2 vs -4.2 wk 12 · n 113 · Phase 3 · secondary NCT02240030
  • -6.5 vs -4.2 wk 12 · n 114 · Phase 3 · secondary NCT02240030
—Not reported
MDS-UPDRS Part II, change—Not reported—Not reported

OFF time, change

Levodopa (Inbrija)
—Not reported
Melevodopa/​carbidopa (Sirio)
—Not reported

ON time without troublesome dyskinesia, change

Levodopa (Inbrija)
—Not reported
Melevodopa/​carbidopa (Sirio)
—Not reported

UPDRS Part III, change

Levodopa (Inbrija)
-9.8 vs -5.9−3.9 vs placebowk 12 · n 114NCT02240030
4 other results
  • -8.5 vs -6.5 wk 12 · n 113 · Phase 3 · secondary NCT02240030
  • -9.0 vs -6.5 wk 12 · n 114 · Phase 3 · secondary NCT02240030
  • -5.2 vs -4.2 wk 12 · n 113 · Phase 3 · secondary NCT02240030
  • -6.5 vs -4.2 wk 12 · n 114 · Phase 3 · secondary NCT02240030
Melevodopa/​carbidopa (Sirio)
—Not reported

MDS-UPDRS Part II, change

Levodopa (Inbrija)
—Not reported
Melevodopa/​carbidopa (Sirio)
—Not reported
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.

Melevodopa/carbidopa (Sirio)
L-dopa accumulation from first to final dose across Cohorts 1/2/3: mean AUC0-t increase V1512 51%/50%/85% vs standard L-dopa/carbidopa 92%/93%/150%; mean Cmax increase V1512 30%/14%/52% vs standard 64%/23%/99%. NCT00491998 · Phase 1/2 · design grade: moderate · publication or press release

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. Levodopa (Inbrija): 4 of 4 rows · Melevodopa/carbidopa (Sirio): 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricLevodopa (Inbrija)
Dropout rate
14.9%CVT-301 High Dosea
NCT02240030 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
show 4 more results
15%CVT-301 Low Dose
NCT02240030 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
28.7%HIgh Dose
NCT02242487 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
38.5%Low Dose
NCT02242487 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
2.5%
NCT02352363 · Phase 3 · monotherapy
Discontinued due to AEs
—CVT-301 High Dosea
NCT02240030 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
show 4 more results
—CVT-301 Low Dose
NCT02240030 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
9.1%HIgh Dose
NCT02242487 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
8.1%Low Dose
NCT02242487 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
—
NCT02352363 · Phase 3 · monotherapy
Serious AEs
1.8%CVT-301 High Dosea
NCT02240030 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
show 4 more results
5.3%CVT-301 Low Dose
NCT02240030 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
8.2%HIgh Dose
NCT02242487 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
14.4%Low Dose
NCT02242487 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
15.5%
NCT02352363 · Phase 3 · monotherapy
Most frequent reported AEs
a
cough 14.9% (placebo 1.8%)
upper respiratory tract 6.1% (placebo 2.7%)
nausea 5.3% (placebo 2.7%)
NCT02240030 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
show 4 more results
cough 15% (placebo 1.8%)
throat irritation 7.1% (placebo 0%)
dyskinesia 4.4% (placebo 0%)
NCT02240030 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
HIgh Dose
cough 14.5%
fall 10.7%
upper respiratory tract infection 7.5%
NCT02242487 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
Low Dose
cough 16.3%
fall 15.7%
upper respiratory tract infection 6.5%
NCT02242487 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
cough 13.3%
fall 8.1%
nasopharyngitis 6.6%
NCT02352363 · Phase 3 · monotherapy

Notes

  1. aPopulation comparability has not been reviewed for 1 of these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Levodopa (Inbrija)

UPDRS Part III -9.83 vs -5.91 placebo score @ 12wk
absolute change · score
NCT02240030 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
show 4 more results
-8.47 vs -6.49 placebo score @ 12wk
NCT02240030 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
-9.04 vs -6.49 placebo score @ 12wk
NCT02240030 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
-5.16 vs -4.18 placebo score @ 12wk
NCT02240030 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
-6.45 vs -4.18 placebo score @ 12wk
NCT02240030 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
OFF to ON Resolution 60 Min 48.7% (n=113) vs 31.3% (n=112) placebo @ 12wk
event count · % of participants
NCT02240030 · Phase 3 · monotherapy · Parkinson's Disease · phase 3 · converted to % from 55 Participants as posted
show 1 more result
49.1% (n=114) vs 31.3% (n=112) placebo @ 12wk*
NCT02240030 · Phase 3 · monotherapy · Parkinson's Disease · phase 3 · converted to % from 56 Participants as posted
PGIC Improvement 54% (n=113) vs 40.2% (n=112) placebo @ 12wk
event count · % of participants
NCT02240030 · Phase 3 · monotherapy · Parkinson's Disease · phase 3 · converted to % from 61 Participants as posted
show 1 more result
61.4% (n=114) vs 40.2% (n=112) placebo @ 12wk*
NCT02240030 · Phase 3 · monotherapy · Parkinson's Disease · phase 3 · converted to % from 70 Participants as posted
OFF to ON 60 Min 54.2% (n=144) @ 52wkDL1
responder rate · % of participants
No placebo or comparator arm
NCT02242487 · Phase 3 · monotherapy · Parkinson's Disease · phase 3 · converted to % from 78 Participants as posted
show 1 more result
60.1% (n=153) @ 52wk*DL2
NCT02242487 · Phase 3 · monotherapy · Parkinson's Disease · phase 3 · converted to % from 92 Participants as posted
OFF Time -0.33 hours @ 4wkDL1
absolute change · hours
No placebo or comparator arm
TV2 (Week 4)
NCT02242487 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
show 1 more result
-0.55 hours @ 4wkDL2
TV2 (Week 4)
NCT02242487 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
OFF Time -0.23 hours @ 12wkDL1
absolute change · hours
No placebo or comparator arm
TV3 (Week 12)
NCT02242487 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
show 1 more result
-0.38 hours @ 12wkDL2
TV3 (Week 12)
NCT02242487 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
OFF Time -0.65 hours @ 24wkDL1
absolute change · hours
No placebo or comparator arm
TV4 (Week 24)
NCT02242487 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
show 1 more result
-0.73 hours @ 24wkDL2
TV4 (Week 24)
NCT02242487 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
OFF Time -0.49 hours @ 36wkDL1
absolute change · hours
No placebo or comparator arm
TV5 (Week 36)
NCT02242487 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
show 1 more result
-0.92 hours @ 36wkDL2
TV5 (Week 36)
NCT02242487 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
OFF Time -0.7 hours @ 52wkDL1
absolute change · hours
No placebo or comparator arm
TV6 (Week 52)
NCT02242487 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
show 1 more result
-0.88 hours @ 52wkDL2
TV6 (Week 52)
NCT02242487 · Phase 3 · monotherapy · Parkinson's Disease · phase 3

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Levodopa (Inbrija)'s landscape · Melevodopa/carbidopa (Sirio)'s landscape